Literature DB >> 2162006

[Initial experiences with substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone].

W Stögmann1, E Bohrn, W Woloszczuk.   

Abstract

In two patients suffering from hypoparathyroidism (HP) whose serum calcium and -phosphate could not be normalized with Vitamin D3-resp. Calcitriol and who continued to have tetanic convulsions, synthetic 1-38 human parathyroid hormone (1-38 hPTH) was used for treatment. In both patients the intravenous administration of 1-38 hPTH provoked a rapid increase of phosphaturia and cAMP-excretion and an increase of the serum calcium level into the normal range. The same effects, only slightly delayed, could be achieved with subcutaneous injections which the patients had learned to do themselves. In case 1, a boy aged 14 years with autoimmune-HP, the daily administration of 8.5 U/kg BW caused hypercalcemia on the 6th day of treatment; therefore the dosis was reduced to alternate day administration. In case 2, a girl aged 17 1/2 years with idiopathic HP, treatment was started with alternate day administration (7.7 U/kg BW/day of injection); serum calcium increased to levels of about 2.2 mmol/1. Side effects could not be seen. Case 1, however, developed resistance to 1-38 hPTH after 10 weeks of therapy. 1-38 hPTH can be classified as an effective substance in the treatment of HP. Optimal dose and frequency of administration cannot yet be pointed out.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162006

Source DB:  PubMed          Journal:  Monatsschr Kinderheilkd        ISSN: 0026-9298            Impact factor:   0.323


  5 in total

1.  Teriparatide (rhPTH 1-34) treatment in the pediatric age: long-term efficacy and safety data in a cohort with genetic hypoparathyroidism.

Authors:  Gerdi Tuli; Raffaele Buganza; Daniele Tessaris; Silvia Einaudi; Patrizia Matarazzo; Luisa de Sanctis
Journal:  Endocrine       Date:  2019-11-08       Impact factor: 3.633

2.  Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.

Authors:  Karen K Winer; Ninet Sinaii; James Reynolds; Donna Peterson; Karen Dowdy; Gordon B Cutler
Journal:  J Clin Endocrinol Metab       Date:  2010-04-14       Impact factor: 5.958

3.  Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism.

Authors:  Karen K Winer; Ninet Sinaii; Donna Peterson; Bruno Sainz; Gordon B Cutler
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

4.  Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism.

Authors:  Karen K Winer; Kara A Fulton; Paul S Albert; Gordon B Cutler
Journal:  J Pediatr       Date:  2014-06-16       Impact factor: 4.406

5.  Perspectives on the Search for a True Physiologic Replacement Therapy for Hypoparathyroidism.

Authors:  Karen K Winer
Journal:  Eur Endocrinol       Date:  2016-03-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.